Here's Why Moderna's Coronavirus Vaccine Could Outsell Pfizer's

Alex Carchidi, The Motley Fool
·4-min read
Here's Why Moderna's Coronavirus Vaccine Could Outsell Pfizer's
Here's Why Moderna's Coronavirus Vaccine Could Outsell Pfizer's

If you could get a coronavirus inoculation this afternoon, you probably wouldn't care if the clinician told you that the shot might feel a bit chilly. Will Moderna's (NASDAQ: MRNA) newly proven vaccine outperform its competitor made by Pfizer (NYSE: PFE) and BioNTech (NASDAQ: BNTX), which is likely to obtain regulatory approval and subsequently hit the market at roughly the same time? Moderna's mRNA-1273 isn't any more effective than Pfizer's candidate when it comes to preventing infection.